Everything you need to know about the next-generation triple receptor agonist
Retatrutide (formerly LY3437943) is an investigational triple receptor agonist developed by Eli Lilly. It uniquely targets three receptors: GIP, GLP-1, and glucagon. In Phase 2 trials, retatrutide demonstrated unprecedented weight loss results of up to 24% of body weight.
The triple mechanism is designed to maximize metabolic benefits while minimizing side effects. The glucagon receptor agonism provides additional thermogenic and lipolytic effects.
Enhances insulin sensitivity and nutrient storage. Amplifies glucose-stimulated insulin secretion.
Promotes satiety, slows gastric emptying, and glucose-dependent insulin secretion.
Stimulates lipolysis and thermogenesis. Provides additional metabolic benefits.
Research Use Only: This product is intended exclusively for laboratory research purposes. Not for human consumption. All research must be conducted in controlled laboratory settings by qualified personnel in accordance with applicable laws and regulations.
